ClinicalTrials.gg

Program

GEN3018

A development code.

Its studies are mostly in Leukemia, Myeloid, Acute, led by Genmab.

Furthest: phase 1, since Jan 27, 20261 company-led study, 1 open or runningNext primary completion: Oct 18, 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Genmab11 open or runningphase 1since Jan 27, 2026Jan 27, 2026Oct 18, 2029phase 1 · NCT07384715

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 27, 2026First study: phase 1 study in Leukemia, Myeloid, AcuteFirst studyNCT07384715 · 78 planned · Denmark, Italy, Spain

Ahead

  1. Oct 18, 2029Primary completion: phase 1 study in Leukemia, Myeloid, AcuteNCT07384715

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07384715Leukemia, Myeloid, Acute · Denmark, Italy, Spain1RecruitingOct 18, 202978

How it is read

Names in the registry

  • “GEN3018”, 1 entry

Codes read as this program: GEN3018.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.